LongIBRXJul 2026
ImmunityBio, Inc.
ImmunityBio's valuation is being assessed against the commercial capacity of its Anktiva franchise. The manager highlights manufacturing facilities capable of producing one…
IBRX
Which hedge funds are long IBRX?
1 published idea on ImmunityBio, Inc. across 1 fund — 1 long and 0 short.
Each entry below comes from a hedge fund's own investor letter, not a 13F filing, so it carries the reasoning behind the position on ImmunityBio, Inc.: the full thesis, the risks the manager flagged, the conviction level and the time horizon. Positions may have changed since the letter was written.